Skip to main content

Alnylam Pharmaceuticals(ALNY-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low309.92
Day High319.50
Open:319.00
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

Top Stories: Alnylam Pharmaceuticals

Select a category then submit the form to load news
Tipranks
Alnylam Grants CEO New Performance-Based Equity Award
GlobeNewswire
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics
Tipranks
Alnylam’s KARDIA-3 Hypertension Trial Reaches Completion, Raising Key Questions for ALNY Investors
Tipranks
Alnylam’s New Phase 1 ALN-4285 Trial: What Early Safety Data Could Mean for ALNY Investors
Tipranks
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), United Therapeutics (UTHR) and Alnylam Pharma (ALNY)
Tipranks
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Moderna (MRNA) and NewAmsterdam Pharma Company (NAMS)
Tipranks
Analysts Offer Insights on Healthcare Companies: Moderna (MRNA) and Alnylam Pharma (ALNY)
GlobeNewswire
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
Tipranks
Canaccord Genuity Keeps Their Buy Rating on Alnylam Pharma (ALNY)
Motley Fool
Why Alnylam Pharmaceuticals Stock Was Soaring on Monday
Tipranks
Cantor Fitzgerald Sticks to Their Hold Rating for Alnylam Pharma (ALNY)
Tipranks
Morgan Stanley Sticks to Its Hold Rating for Alnylam Pharma (ALNY)
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Alnylam Pharma (ALNY), Sysmex (SSMXF)
Tipranks
Chardan Capital Sticks to Its Buy Rating for Alnylam Pharma (ALNY)
Tipranks
Execution Risks Loom as Alnylam Races to Scale Global Operations for AMVUTTRA and 2030 Growth Ambitions
Tipranks
Alnylam Pharmaceuticals Projects Powerful Growth After Breakout Year
Motley Fool
Why Alnylam Pharmaceuticals Stock Slipped Today
Tipranks
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Amgen (AMGN) and Indivior (INDV)
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Danaher (DHR), Nurix Therapeutics (NRIX)
Tipranks
Bank of America Securities Remains a Buy on Alnylam Pharma (ALNY)
Motley Fool
Should You Buy Alnylam Pharmaceuticals Before Feb. 12?
Tipranks
Analysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Ascendis Pharma (ASND)
Tipranks
Bernstein Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
Tipranks
Evercore ISI Sticks to Its Buy Rating for Alnylam Pharma (ALNY)
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Alnylam Pharma (ALNY), Foghorn Therapeutics (FHTX)
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Alnylam Pharma (ALNY), GeneDx Holdings (WGS) and Masimo (MASI)
Tipranks
Truist Financial Keeps Their Buy Rating on Alnylam Pharma (ALNY)
Tipranks
Oppenheimer Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
Tipranks
Wells Fargo Sticks to Its Hold Rating for Alnylam Pharma (ALNY)
Tipranks
Alnylam Pharma Announces Convertible Notes Buyback
Motley Fool
Is Alnylam Pharmaceuticals a Millionaire Maker?
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks

Profile

Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic disease and hepatic infectious disease. The company's lead drug-Onpattro received regulatory approvals in the United States and Europe for the treatment of hereditary transthyretin-mediated amyloidosis in adults. The FDA approved Givlaari for acute hepatic porphyria. The FDA approved Oxlumo injection for subcutaneous use, for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients. Moreover, the company is evaluating inclisiran for hypercholesterolemia in partnership with The Medicines Company acquired by Novartis. The FDA approved Leqvio to reduce low-density lipoprotein cholesterol with two doses a year..

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.